Fusion Pharmaceuticals and BWXT Medical Announce Actinium-225 Partnership to Scale Supply for Developing Targeted Alpha Therapies
05 January 2023
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (NYSE: BWXT), today announced that the companies have entered into a preferred partner agreement for the supply of actinium-225.
BWXT Promotes Chip Whitford to Senior Vice President and General Counsel
04 January 2023
BWX Technologies, Inc. (NYSE: BWXT) has promoted Ronald O. (Chip) Whitford, Jr. to the position of senior vice president, general counsel, chief compliance officer and corporate secretary, effective January 2, 2023.
BWXT Names Omar Meguid Chief Digital Officer
03 January 2023
BWX Technologies, Inc. (NYSE: BWXT) has named Omar Meguid as senior vice president and chief digital officer effective January 1, 2023.